Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Inspection Record
Guardian Pharmacy Services — FDA 483 Findings
Inspectors Patty P Kaewussdangkul · Lori G Cantin · Bonita S ChesterThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Records of the calibration checks of automatic, mechanical or electronic equipment, including computers or related systems are not maintained.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.
Air is recirculated to production areas, without adequate measures to control recirculation ofdust.
The responsibilities and procedures applicable to the quality control unit are not fully followed.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
There is a failure to thoroughly review the failure o fa batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.
Written procedures are not followed for the cleaning and maintenance ofequipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Records are not kept for the cleaning and sanitizing of equipment.
There is no written testing program designed to assess the stability characteristics of drug products.
Equipment used in the manufacture, processing, packing or holding of drug products is not of appropriate design to facilitate operations for its cleaning and maintenance.
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Written records are not always made of investigations into unexplained discrepancies.
About this record
Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.
This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.
Translation and classification are automated and may differ in nuance from the source.
